[转移贴]Debio 025’s endpoint for the cure in 76% of patients with HCV
原贴由suzhuang发表于 2011-7-24 21:40Debio 025 (alisporivir) is the first in a new class of drugs called cyclophilin inhibitors, which could become part of the future standard of care for hepatitis C. Debio 025 has been licenced to Novartis for the entire world except Japan.
Debio 025 has a low potential for resistance selection. Debiopharm obtained positive efficacy results of a phase IIa study with Debio 025.
Debio 025 has been shown to have a potent inhibitory effect on hepatitis C virus (HCV) replication when used alone or in combination with Interferon (IFN).
Novartis presented new data at EASL in March 2011, showing that Debio 025 has met its primary endpoint for achieving viral cure (24 weeks after stopping treatment) in 76% of patients with chronic hepatitis C. A pivotal Phase III study with Debio 025 commenced recently to evaluate the efficacy and safety of Debio 025 combined with standard of care and enrolling previously untreated HCV G1 patients. Other Phase II studies are ongoing in other patient populations i.e., G1 treatment-experienced patients and G2 and G3 treatment-naive patients.
页:
[1]